Home › Pituitary ACTH Hypersecretion
Pituitary ACTH Hypersecretion clinical trials recruiting in the U.S.
10 studies for Pituitary ACTH Hypersecretion are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 70 · All sexes · Updated Sep 22, 2026 · NCT00001595Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04543253Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 90 · All sexes · Updated Sep 16, 2026 · NCT03831958A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 21, 2026 · NCT06471829Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT05971758FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT07460232DDAVP for Pituitary Adenoma
Recruiting
Ages 8 to 99 · All sexes · Updated Apr 9, 2026 · NCT04569591Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RecruitingObservational study
All ages · All sexes · Updated Jan 13, 2026 · NCT07335315Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RecruitingObservational study
Ages 14 and older · All sexes · Updated Oct 23, 2025 · NCT03364803Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2025 · NCT03774446From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.